DHR Stock: Morgan Stanley Reaffirms Buy but Cuts Price Target as Danaher Trades Near 52-Week Low

April 24, 2026

By TrendSpider Editor

DHR Stock: Morgan Stanley Reaffirms Buy but Cuts Price Target as Danaher Trades Near 52-Week Low

Morgan Stanley analyst Kallum Titchmarsh maintained a Buy rating on Danaher Corporation but trimmed the price target from $270 to $255, signaling tempered near-term expectations even as conviction in the long-term thesis holds. DHR currently trades at $178.655, sitting uncomfortably close to its 52-week low of $175.00, well beneath the new $255 target and far below the 52-week high of $242.75. The stock edged up just 0.07% on the session, offering little momentum heading into the weekend.

Key Drivers of the DHR Stock Move

Main Catalyst: Morgan Stanley's Kallum Titchmarsh confirmed a Buy rating on DHR while cutting the price target by $15, moving it from $270 to $255. The action represents a maintained bullish stance paired with a meaningful reduction in the firm's 12-month upside estimate.
Bull Case: Even at the revised $255 price target, DHR trades at a significant discount to where Morgan Stanley sees fair value. At the current price of $178.655, the stock would need to appreciate roughly 42% to reach that target, representing a sizable implied upside for investors willing to hold through a period of uncertainty.
Bear Case: A price target cut from $270 to $255 suggests the analyst community is dialing back expectations, and with DHR sitting just $3.655 above its 52-week low of $175.00, downside risk is tangible. The stock has surrendered the bulk of its 52-week range, which spans from $175.00 to $242.75, and the flat session gain of 0.07% reflects a lack of buying conviction at current levels.

The forward setup for DHR is a study in contrasting signals. A maintained Buy from a firm like Morgan Stanley provides a floor of institutional credibility, but the price target reduction tells a more cautious story about near-term fundamentals, likely reflecting continued softness in life sciences and biotech end markets that have weighed on the business. Danaher has been navigating a post-pandemic normalization cycle in its bioprocessing segment, and the path back to meaningful revenue and earnings growth has proven slower than many originally anticipated. With the stock hugging its 52-week low, the coming weeks will be pivotal in determining whether buyers step in to defend this level or whether the support gives way entirely.

DHR Analyst Ratings and Price Targets

Morgan Stanley analyst Kallum Titchmarsh issued the sole rating action on DHR as of April 24, 2026. The firm confirmed its Buy rating while reducing its price target to $255 from a prior target of $270. The consensus average price target currently stands at $255, aligning precisely with Morgan Stanley's revised figure. There were no upgrades or downgrades in the most recent action window, with the total action count standing at one.

DHR Seasonality

Late April historically coincides with earnings season activity for large-cap industrials and life sciences companies, a period that can introduce elevated volatility as guidance updates reset institutional price targets. For a name like Danaher, analyst revisions in this window often carry outsized weight given the stock's sensitivity to forward earnings visibility.

DHR Relative Performance

DHR's 0.07% gain on Friday is essentially flat, underscoring a lack of directional conviction relative to broader market action. Trading at $178.655 against a 52-week high of $242.75 means the stock has declined approximately 26% from its peak, a notably steeper drawdown than what many large-cap industrial peers have experienced over the same period. Until DHR can establish a credible base above its 52-week low of $175.00, it remains a relative underperformer within the life sciences tools and diversified industrials space.